Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities

Marie E. Gardner, Daniel C Malone, Mark Sey, Maude A. Babington

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Depression is a common, treatable disorder among nursing facility residents. Objective: The purpose of this study was to examine medication use and cost between two groups of patients: (1) persons treated with mirtazapine, as comparedwith (2) persons taking other antidepressants. Design: This study was a retrospective chart review of long-term care patients. Consultant pharmacists collected data on patients who were receiving selective serotonin reuptake inhibitors (SSRIs), venlafaxine, nefazodone, or mirtazapine. Setting: Nursing facilities that were geographically dispersed throughout the United States. Participants: We studied patients greater than 65 years of age with major depressive disorder or a depression-related diagnosis and receiving antidepressant treatment for at least 3 months. Patients with bipolar-induced depression were excluded as well as those receiving tricyclic antidepressants. Results: The two groups were similar in terms of age, but those receiving mirtazapine had lower body weight and body mass index. Patients on mirtazapine were less likely to be taking a sedative/hypnotic (P = 0.006). This was primarily the result of fewer patients in the mirtazapine group taking lorazepam (P = 0.03). There was no difference between the two groups regarding their use of other psychotropic medications, including multiple antidepressants, antipsychotics, anticonvulsants, acetylcholinesterase inhibitors, or appetite stimulants. Monthly medication costs were less for those patients receiving mirtazapine ($82.83) as compared with other antidepressants ($97.03) (P <0.0001). Conclusions: The results of this study suggest that patients receiving mirtazapine are less likely to be on anxiolytic/hypnotic agents. The findings also suggest that medication costs are less when mirtazapine is used compared with other antidepressants.

Original languageEnglish (US)
Pages (from-to)101-106
Number of pages6
JournalJournal of the American Medical Directors Association
Volume5
Issue number2
StatePublished - Mar 2004

Fingerprint

Anti-Anxiety Agents
Long-Term Care
Antidepressive Agents
Hypnotics and Sedatives
Costs and Cost Analysis
Appetite Stimulants
Nursing
Depression
mirtazapine
Lorazepam
Tricyclic Antidepressive Agents
Cholinesterase Inhibitors
Major Depressive Disorder
Serotonin Uptake Inhibitors
Consultants
Bipolar Disorder
Pharmacists
Anticonvulsants
Antipsychotic Agents
Body Mass Index

Keywords

  • Anxiolytic
  • Depression
  • Mirtazapine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities. / Gardner, Marie E.; Malone, Daniel C; Sey, Mark; Babington, Maude A.

In: Journal of the American Medical Directors Association, Vol. 5, No. 2, 03.2004, p. 101-106.

Research output: Contribution to journalArticle

@article{5453e39c0b1544729431a081d8f51ad5,
title = "Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities",
abstract = "Background: Depression is a common, treatable disorder among nursing facility residents. Objective: The purpose of this study was to examine medication use and cost between two groups of patients: (1) persons treated with mirtazapine, as comparedwith (2) persons taking other antidepressants. Design: This study was a retrospective chart review of long-term care patients. Consultant pharmacists collected data on patients who were receiving selective serotonin reuptake inhibitors (SSRIs), venlafaxine, nefazodone, or mirtazapine. Setting: Nursing facilities that were geographically dispersed throughout the United States. Participants: We studied patients greater than 65 years of age with major depressive disorder or a depression-related diagnosis and receiving antidepressant treatment for at least 3 months. Patients with bipolar-induced depression were excluded as well as those receiving tricyclic antidepressants. Results: The two groups were similar in terms of age, but those receiving mirtazapine had lower body weight and body mass index. Patients on mirtazapine were less likely to be taking a sedative/hypnotic (P = 0.006). This was primarily the result of fewer patients in the mirtazapine group taking lorazepam (P = 0.03). There was no difference between the two groups regarding their use of other psychotropic medications, including multiple antidepressants, antipsychotics, anticonvulsants, acetylcholinesterase inhibitors, or appetite stimulants. Monthly medication costs were less for those patients receiving mirtazapine ($82.83) as compared with other antidepressants ($97.03) (P <0.0001). Conclusions: The results of this study suggest that patients receiving mirtazapine are less likely to be on anxiolytic/hypnotic agents. The findings also suggest that medication costs are less when mirtazapine is used compared with other antidepressants.",
keywords = "Anxiolytic, Depression, Mirtazapine",
author = "Gardner, {Marie E.} and Malone, {Daniel C} and Mark Sey and Babington, {Maude A.}",
year = "2004",
month = "3",
language = "English (US)",
volume = "5",
pages = "101--106",
journal = "Journal of the American Medical Directors Association",
issn = "1525-8610",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities

AU - Gardner, Marie E.

AU - Malone, Daniel C

AU - Sey, Mark

AU - Babington, Maude A.

PY - 2004/3

Y1 - 2004/3

N2 - Background: Depression is a common, treatable disorder among nursing facility residents. Objective: The purpose of this study was to examine medication use and cost between two groups of patients: (1) persons treated with mirtazapine, as comparedwith (2) persons taking other antidepressants. Design: This study was a retrospective chart review of long-term care patients. Consultant pharmacists collected data on patients who were receiving selective serotonin reuptake inhibitors (SSRIs), venlafaxine, nefazodone, or mirtazapine. Setting: Nursing facilities that were geographically dispersed throughout the United States. Participants: We studied patients greater than 65 years of age with major depressive disorder or a depression-related diagnosis and receiving antidepressant treatment for at least 3 months. Patients with bipolar-induced depression were excluded as well as those receiving tricyclic antidepressants. Results: The two groups were similar in terms of age, but those receiving mirtazapine had lower body weight and body mass index. Patients on mirtazapine were less likely to be taking a sedative/hypnotic (P = 0.006). This was primarily the result of fewer patients in the mirtazapine group taking lorazepam (P = 0.03). There was no difference between the two groups regarding their use of other psychotropic medications, including multiple antidepressants, antipsychotics, anticonvulsants, acetylcholinesterase inhibitors, or appetite stimulants. Monthly medication costs were less for those patients receiving mirtazapine ($82.83) as compared with other antidepressants ($97.03) (P <0.0001). Conclusions: The results of this study suggest that patients receiving mirtazapine are less likely to be on anxiolytic/hypnotic agents. The findings also suggest that medication costs are less when mirtazapine is used compared with other antidepressants.

AB - Background: Depression is a common, treatable disorder among nursing facility residents. Objective: The purpose of this study was to examine medication use and cost between two groups of patients: (1) persons treated with mirtazapine, as comparedwith (2) persons taking other antidepressants. Design: This study was a retrospective chart review of long-term care patients. Consultant pharmacists collected data on patients who were receiving selective serotonin reuptake inhibitors (SSRIs), venlafaxine, nefazodone, or mirtazapine. Setting: Nursing facilities that were geographically dispersed throughout the United States. Participants: We studied patients greater than 65 years of age with major depressive disorder or a depression-related diagnosis and receiving antidepressant treatment for at least 3 months. Patients with bipolar-induced depression were excluded as well as those receiving tricyclic antidepressants. Results: The two groups were similar in terms of age, but those receiving mirtazapine had lower body weight and body mass index. Patients on mirtazapine were less likely to be taking a sedative/hypnotic (P = 0.006). This was primarily the result of fewer patients in the mirtazapine group taking lorazepam (P = 0.03). There was no difference between the two groups regarding their use of other psychotropic medications, including multiple antidepressants, antipsychotics, anticonvulsants, acetylcholinesterase inhibitors, or appetite stimulants. Monthly medication costs were less for those patients receiving mirtazapine ($82.83) as compared with other antidepressants ($97.03) (P <0.0001). Conclusions: The results of this study suggest that patients receiving mirtazapine are less likely to be on anxiolytic/hypnotic agents. The findings also suggest that medication costs are less when mirtazapine is used compared with other antidepressants.

KW - Anxiolytic

KW - Depression

KW - Mirtazapine

UR - http://www.scopus.com/inward/record.url?scp=1642363282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642363282&partnerID=8YFLogxK

M3 - Article

C2 - 14984621

AN - SCOPUS:1642363282

VL - 5

SP - 101

EP - 106

JO - Journal of the American Medical Directors Association

JF - Journal of the American Medical Directors Association

SN - 1525-8610

IS - 2

ER -